Sinaptica Therapeutics Headquarters & Office Locations

Sinaptica Therapeutics is headquartered in Cambridge, Massachusetts, United States. Founded in 2023, the company has 2 recorded locations and employs approximately 16 people worldwide.

Where is Sinaptica Therapeutics's main office?

Sinaptica Therapeutics's main headquarters office is located at 245 First Street 18th Floor, Cambridge, Massachusetts 02142, United States. This is the company's primary corporate address.

Sinaptica Therapeutics regional offices

Beyond its headquarters in Cambridge, Sinaptica Therapeutics has recorded locations in United States.

What does Sinaptica Therapeutics do?

Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the company's neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.